278 related articles for article (PubMed ID: 29636326)
1. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.
Delfau-Larue MH; van der Gucht A; Dupuis J; Jais JP; Nel I; Beldi-Ferchiou A; Hamdane S; Benmaad I; Laboure G; Verret B; Haioun C; Copie-Bergman C; Berriolo-Riedinger A; Robert P; Casasnovas RO; Itti E
Blood Adv; 2018 Apr; 2(7):807-816. PubMed ID: 29636326
[TBL] [Abstract][Full Text] [Related]
2. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.
Meignan M; Cottereau AS; Versari A; Chartier L; Dupuis J; Boussetta S; Grassi I; Casasnovas RO; Haioun C; Tilly H; Tarantino V; Dubreuil J; Federico M; Salles G; Luminari S; Trotman J
J Clin Oncol; 2016 Oct; 34(30):3618-3626. PubMed ID: 27551111
[TBL] [Abstract][Full Text] [Related]
3. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
Cottereau AS; Rebaud L; Trotman J; Feugier P; Nastoupil LJ; Bachy E; Flinn IW; Haioun C; Ysebaert L; Bartlett NL; Tilly H; Casasnovas O; Ricci R; Portugues C; Buvat I; Meignan M; Morschhauser F
Ann Oncol; 2024 Jan; 35(1):130-137. PubMed ID: 37898239
[TBL] [Abstract][Full Text] [Related]
4. Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
Cottereau AS; El-Galaly TC; Becker S; Broussais F; Petersen LJ; Bonnet C; Prior JO; Tilly H; Hutchings M; Casasnovas O; Meignan M
J Nucl Med; 2018 Apr; 59(4):589-595. PubMed ID: 28864629
[TBL] [Abstract][Full Text] [Related]
5. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
[TBL] [Abstract][Full Text] [Related]
6. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.
Le Goff E; Blanc-Durand P; Roulin L; Lafont C; Loyaux R; MBoumbae DL; Benmaad I; Claudel A; Poullot E; Robe C; Gricourt G; Aissat A; Copie-Bergman C; Lemonnier F; Gaulard P; Itti E; Haioun C; Delfau-Larue MH
Br J Haematol; 2023 Jul; 202(1):54-64. PubMed ID: 37038217
[TBL] [Abstract][Full Text] [Related]
7. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718
[TBL] [Abstract][Full Text] [Related]
8. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
[TBL] [Abstract][Full Text] [Related]
9. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S
J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer:
Morbelli S; Alama A; Ferrarazzo G; Coco S; Genova C; Rijavec E; Bongioanni F; Biello F; Dal Bello MG; Barletta G; Massollo M; Vanni I; Piva R; Nieri A; Bauckneht M; Sambuceti G; Grossi F
J Nucl Med; 2017 Nov; 58(11):1764-1769. PubMed ID: 28450567
[TBL] [Abstract][Full Text] [Related]
11. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin's lymphoma.
Pinochet P; Texte E; Stamatoullas-Bastard A; Vera P; Mihailescu SD; Becker S
Sci Rep; 2021 Dec; 11(1):23195. PubMed ID: 34853386
[TBL] [Abstract][Full Text] [Related]
13. Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden.
Leccisotti L; Maccora D; Malafronte R; D'Alò F; Maiolo E; Annunziata S; Rufini V; Giordano A; Hohaus S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2783-2791. PubMed ID: 35779106
[TBL] [Abstract][Full Text] [Related]
14. A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma.
Mozas P; Casanueva-Eliceiry S; Rivero A; Serna Á; Simó M; Rodríguez S; Rivas-Delgado A; Nadeu F; Correa JG; Piñeyroa JA; Pérez-Valencia AI; Guinetti-Ortiz K; Gómez-Hernando M; Giné E; Delgado J; Villamor N; Campo E; Magnano L; Abrisqueta P; Setoain X; López-Guillermo A
Hematol Oncol; 2024 Jan; 42(1):e3235. PubMed ID: 37942762
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma.
Draye-Carbonnier S; Camus V; Becker S; Tonnelet D; Lévêque E; Zduniak A; Jardin F; Tilly H; Vera P; Decazes P
Sci Rep; 2024 Apr; 14(1):8033. PubMed ID: 38580734
[TBL] [Abstract][Full Text] [Related]
16. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
17. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
Fernandez-Garcia D; Hills A; Page K; Hastings RK; Toghill B; Goddard KS; Ion C; Ogle O; Boydell AR; Gleason K; Rutherford M; Lim A; Guttery DS; Coombes RC; Shaw JA
Breast Cancer Res; 2019 Dec; 21(1):149. PubMed ID: 31856868
[TBL] [Abstract][Full Text] [Related]
18. First Extensive Analysis of
Louarn N; Galicier L; Bertinchamp R; Lussato D; Montravers F; Oksenhendler É; Merlet P; Gérard L; Vercellino L
J Clin Oncol; 2022 Apr; 40(12):1346-1355. PubMed ID: 35073166
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline
Delaby G; Hubaut MA; Morschhauser F; Besson A; Huglo D; Herbaux C; Baillet C
Leuk Lymphoma; 2020 Jul; 61(7):1584-1591. PubMed ID: 32100597
[TBL] [Abstract][Full Text] [Related]
20. Influence of the methodological aspects of the dichotomization of total metabolic tumor volume measured through baseline fluorine-18 fluorodeoxyglucose PET on survival prediction in lymphoma.
Lue KH; Chen YH; Wu YF; Liu SH
Nucl Med Commun; 2023 Jan; 44(1):74-80. PubMed ID: 36514929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
